NASDAQ · IBRX
Healthcare · Biotechnology
$10.00
Up+$0.09 (+0.91%)
Updated Oct 16, 2026, 7:39 AM
SID Score
6.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · IBRX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 15, 2026
IBRX closed at $10.00 after 21 trading sessions, up 18.20% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | $10.20 | $10.50 | $9.815 | $10.00 | 20.01M |
| Oct 14, 2026 | $9.69 | $10.455 | $9.35 | $9.91 | 30.23M |
| Oct 13, 2026 | $10.00 | $10.0599 | $9.56 | $9.80 | 11.62M |
| Oct 12, 2026 | $10.59 | $10.62 | $10.05 | $10.12 | 11.06M |
| Oct 9, 2026 | $9.95 | $10.80 | $9.87 | $10.51 | 18.66M |
| Oct 8, 2026 | $9.63 | $10.045 | $9.43 | $9.91 | 10.49M |
| Oct 7, 2026 | $9.50 | $9.93 | $9.33 | $9.75 | 11.78M |
| Oct 6, 2026 | $10.325 | $10.36 | $9.61 | $9.69 | 16.89M |
| Oct 5, 2026 | $10.76 | $10.81 | $10.125 | $10.38 | 16.87M |
| Oct 2, 2026 | $9.39 | $10.55 | $9.39 | $10.285 | 31.25M |
| Oct 1, 2026 | $9.28 | $9.40 | $9.07 | $9.28 | 12.31M |
| Sep 30, 2026 | $8.92 | $10.09 | $8.90 | $9.44 | 27.29M |
| Sep 29, 2026 | $8.52 | $8.88 | $8.52 | $8.83 | 8.37M |
| Sep 28, 2026 | $8.39 | $8.9787 | $8.26 | $8.52 | 10.41M |
| Sep 25, 2026 | $8.76 | $8.84 | $8.41 | $8.44 | 5.82M |
| Sep 24, 2026 | $8.50 | $8.675 | $8.31 | $8.64 | 8.98M |
| Sep 23, 2026 | $9.26 | $9.29 | $8.60 | $8.63 | 13.95M |
| Sep 22, 2026 | $8.45 | $9.48 | $8.37 | $9.29 | 21.13M |
| Sep 21, 2026 | $8.72 | $8.87 | $8.26 | $8.45 | 12.24M |
| Sep 18, 2026 | $8.46 | $8.53 | $8.20 | $8.48 | 18.43M |
| Sep 17, 2026 | $8.14 | $8.80 | $8.12 | $8.46 | 19.16M |
The latest Smart Investors Daily articles mentioning IBRX.
Company
Market Activity
Research & News
IBRX research
Company profile and research snapshot.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 15, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 2, 2026 | HC Wainwright & Co. | Buy | — |
| May 21, 2026 | BTIG | Buy | — |
| May 20, 2026 | HC Wainwright & Co. | Buy | — |
| May 5, 2026 | D. Boral Capital | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 8, 2026
CULVER CITY, Calif., October 08, 2026--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that Dr. Patrick Soon-Shiong, its Founder, Executive Chairman and Global Chief Scientific and Medical Officer, will participate virtually in a fireside chat at the Piper Sandler Virtual Oncology Symposium, taking place October 15-16, 2026.
Yahoo · Oct 8, 2026
ImmunityBio (IBRX) is preparing to share new data at the Thoracic Rare Cancer Symposium in Ottawa on October 2, 2026. This is drawing fresh attention to how its immunotherapy pipeline is being valued. Over the past year ImmunityBio has shifted from a niche biotech story to one that traders watch closely, with the latest symposium appearance adding to a series of catalysts that have coincided with very strong momentum. The share price has a 30 day return of 20.67% and a year to date share...
Yahoo · Oct 8, 2026
The initiative aligns with Soon-Shiong’s ‘Immunotherapy 2.0’ vision, combining immune treatments, diagnostics and monitoring to help prevent cancer recurrence.
Yahoo · Oct 5, 2026
Founder Patrick Soon-Shiong outlined an ‘Immunotherapy 2.0’ approach aimed at strengthening immune defenses and preventing cancer recurrence.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IBRX.
